US 12,064,428 B2
Kinase inhibitor salts and compositions thereof
Fang-Yu Liu, San Jose, CA (US); K. C. Sung, Tainan (TW); Chin-Yao Yang, Tainan (TW); Chi-Cheng Lin, Tainan (TW); Yi-Hsin Lin, Tainan (TW); and Li Qiao, San Jose, CA (US)
Assigned to HANDA ONCOLOGY, LLC, San Jose, CA (US)
Filed by HANDA ONCOLOGY, LLC, San Jose, CA (US)
Filed on May 17, 2021, as Appl. No. 17/321,864.
Application 17/321,864 is a continuation of application No. 17/167,719, filed on Feb. 4, 2021, granted, now 11,052,088.
Application 17/167,719 is a continuation of application No. 16/701,941, filed on Dec. 3, 2019, granted, now 11,007,195, issued on May 18, 2021.
Application 16/701,941 is a continuation of application No. PCT/US2019/036947, filed on Jun. 13, 2019.
Claims priority of provisional application 62/811,368, filed on Feb. 27, 2019.
Claims priority of provisional application 62/791,356, filed on Jan. 11, 2019.
Claims priority of provisional application 62/685,411, filed on Jun. 15, 2018.
Prior Publication US 2021/0283133 A1, Sep. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/506 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61P 35/02 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61P 35/02 (2018.01)] 49 Claims
 
1. A capsule comprising a dasatinib lauryl sulfate composition wherein the dasatinib lauryl sulfate composition comprises:
(i) about 1 wt % to 80 wt % of a crystalline dasatinib lauryl sulfate salt characterized by an x-ray powder diffraction (XRPD) pattern with four or more 2θ peaks selected from the group consisting of 6.5±0.2, 9.5±0.2, 10.2±0.2, 12.7±0.2, 17.1±0.2, 18.1±0.2, 19.1±0.2, 21.1±0.2, 22.2±0.2, 24.1±0.2, 24.7±0.2 and 28.5±0.2; and
(ii) about 1 wt % to about 60 wt % of a wetting agent, an emulsifying agent, a solubilizing agent, a surfactant or a combination thereof.